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Abstract
Objectives: The aim of this study was to evaluate the effects of prostaglandin E2 (PGE2) on 
haematopoietic stem cell (HSC) function and determine its mechanism of action.
Materials and methods: HSC were exposed to PGE2 for 2 h and effects on their homing, 
engraftment and self-renewal evaluated in vivo. Effects of PGE2 on HSC cell cycle, CXCR4 
expression and migration to SDF-1a were analysed in vitro. Apoptosis was evaluated by 
examination of survivin expression and active caspase-3 levels.
Results: Equivalent haematopoietic reconstitution was demonstrated using 4-fold fewer PGE2-
treated cells compared to controls. Multilineage reconstitution was stable on secondary 
transplantation, indicating that PGE2 affects long-term repopulating HSC (LT-HSC) and that 
enhanced chimaerism of PGE2-pulsed cells results from their initial treatment. PGE2 increased 
CXCR4 expression on mouse and human HSC, increased their migration to SDF-1α in vitro and 
enhanced in vivo marrow homing 2-fold, which was blocked by a CXCR4 receptor antagonist. 
PGE2 pulse exposure reduced apoptosis of mouse and human HSC, with increase in endogenous 
caspase inhibitor survivin, and concomitant decrease in active caspase-3. Two-fold more HSC 
entered the cell cycle and proliferated within 24 h after PGE2 pulse exposure.
Conclusions: These studies demonstrate that short-term PGE2 exposure enhances HSC function 
and supports the concept of utility of PGE2 as an ex vivo strategy to improve function of 
haematopoietic grafts, particularly those where HSC numbers are limited.
Introduction
Prostaglandins (PGs) are extremely active short-lived lipids that act locally in a paracrine or 
autocrine fashion. There are no organs, tissues or cells in the body that are not affected by 
these bioactive lipids, either directly or through accessory mechanisms. All nucleated cells 
synthesize PGs by cleavage of the essential fatty acid, arachidonic acid from membrane 
phospholipids by phospholipase A2, oxidation of free arachidonic acid by two 
cyclooxygenase enzymes (COX1 and COX2) and subsequent isomerization to an 
intermediate form, and synthesis of various mature PGs by specific synthases (2,3). A 
schematic outline of prostaglandin E2 (PGE2) biosynthesis is shown in Fig. 1. PGE2 is the 
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predominant metabolite of arachidonic acid and is the most abundant eicosanoid (4,5). PGE2 
has been implicated in regulation of numerous physiological systems, and is the primary 
mediator of symptoms of fever (6) and inflammation (4,7), a regulator of atherosclerosis, 
blood pressure and strokes (7), and is involved in neoplastic transformation and cancer cell 
effects on host responses (4,8). Effects of PGE2 are mediated through four highly conserved 
G-protein-coupled receptors (EP1–4) with overlapping as well as distinct signalling 
pathways (9,10) that can lead to seemingly opposing effects. EP receptor levels vary among 
tissues, and signalling pathways downstream of the same receptors can vary depending upon 
cell lineage.
Previously we have shown that PGE2 regulates haematopoiesis, affecting both 
haematopoietic stem cell (HSC) and progenitor cell (HPC) functions. PGE2 inhibits 
myelopoiesis in vitro and in vivo (11–13), and participates in a negative feedback loop 
regulating myeloid progenitor cell expansion (12,14,15). In contrast to its effects on 
myelopoiesis, PGE2 promotes erythroid and multipotential colony formation in vitro 
(16,17). Early studies showed that short-term ex vivo treatment of bone marrow cells with 
PGE2 could enhance progenitor cell proliferation (18,19); however, in vivo dosing led to 
little or no effect (20). We later showed that pulse exposure of mouse or human bone marrow 
cells to PGE2 stimulated proliferation, cycling and differentiation of quiescent cells leading 
to an increase in cycling HPC, suggesting that PGE2 enhances HSC function (21–23). These 
studies also clearly defined that dose, timing and length of exposure of haematopoietic cells 
to PGE2 were critical factors defining stimulatory versus inhibitory effects on 
haematopoiesis. However, while these studies were the first to clearly implicate PGE2 in 
positive regulation of haematopoiesis, stem cell function cannot be defined solely based on 
clonogenic assays. Elucidation of the effects of PGE2 on HSC function requires 
demonstration that transplanted cells can repopulate haematopoiesis in myeloablated hosts 
(24). Recently, effects of PGE2 on haematopoietic stem cell function have been revisited and 
studies in zebrafish and mice (25,26) validate the stimulatory effects of PGE2 on HSC 
function that were suggested in earlier in vitro studies. In addition, we have defined 
mechanisms of action of PGE2 on HSC function, particularly on HSC homing and self-
renewal, which suggest that short-term exposure of haematopoietic grafts to PGE2 can be 
utilized for therapeutic benefit in HSC transplantation (25). In this study, we describe pre-
clinical findings supporting the therapeutic ex vivo utility of PGE2 as a facilitator of HSC 
engraftment.
Materials and methods
Mouse and human cord blood
C57Bl ⁄ 6 (CD45.2) mice were purchased from Jackson Laboratories (Bar Harbor, ME, 
USA). B6.SJL-PtrcA-Pep3B ⁄ BoyJ (BOYJ) (CD45.1), C57Bl ⁄ 6 X BOYJ-F1 (CD45.1 ⁄ 
CD45.2) and NOD.Cg-Prkdcscid IL2rgtm1Wjl ⁄ Sz (NSG) mice were bred in-house. Human 
umbilical cord blood (UCB) was obtained from Wishard Hospital, India-napolis, IN, with 
IRB approval.
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Flow cytometry
For detection of SKL cells, streptavidin conjugated with PE-Cy7 [to stain for biotinylated 
MACS lineage antibodies (Miltenyi Biotech, Auburn, CA, USA)], c-kit-APC, Sca-1-PE or 
APC-Cy7, CD45.1-PE, CD45.2-FITC and CD34-PE were used (BD Biosciences, San Jose, 
CA, USA). For SLAM SKL, we used Sca-1-PE-Cy7, c-kit-FITC, CD150-APC 
(eBiosciences, San Diego, CA, USA), CD48-biotin (eBiosciences) and streptavidin-PE. 
UCB CD34+ cells were detected using anti-human-CD34-APC. For multi-lineage analysis, 
APC-Cy7-Mac-1, PE-Cy7-B-220 and APC-CD3 were used (BD Biosciences).
PGE2 pulse exposure
Cells were incubated with 16,16-dimethyl prostaglandin E2 (dmPGE2) (Cayman Chemicals, 
Ann Arbor, MI, USA) (reconstituted in 100% ethanol) diluted in media, on ice, for 2 h. 
After incubation, cells were washed twice before use. Vehicle-treated cells were pulsed with 
equivalent concentration of ethanol.
Limiting dilution competitive and non-competitive transplantation
Whole bone marrow cells (CD45.2) were treated with 1 µM dmPGE2 or 0.001% EtOH, 
washed, admixed with 2 × 105 congenic CD45.1 competitor marrow cells at various ratios, 
and transplanted into lethally irradiated CD45.1 ⁄ CD45.2 mice. Peripheral blood CD45.1 
and CD45.2 cells were determined monthly by FACS. HSC frequency was quantified by 
Poisson statistics using L-CALC software (Stem Cell Technologies, Vancouver BC, 
Canada). Competitive repopulating units (CRU) were calculated as described by Harrison 
(24). For secondary transplantation, 2 × 106 WBM from previously transplanted CD45.1 ⁄ 
CD45.2 mice at 20 weeks post-transplant were injected into lethally irradiated CD45.1 ⁄ 
CD45.2 mice in a non-competitive fashion.
HSPC homing
For competitive homing studies, SKL cells from CD45.2 and CD45.1 mice were FACS 
sorted, treated with dmPGE2 or vehicle and 3 × 104 CD45.1 (vehicle or dmPGE2 treated) 
plus 3 × 104 CD45.2 (dmPGE2 or vehicle treated) SKL cells transplanted into lethally 
irradiated CD45.1 ⁄ CD45.2 mice. Homed CD45.1 and CD45.2 SKL cells in bone marrow 
were determined after 16 h. To evaluate the role of CXCR4 in homing, Linneg CD45.2 cells 
were treated with vehicle or 1 µM dmPGE2 plus 10 µM AMD3100 (AnorMed Inc., 
Vancouver, BC, Canada), and 2 × 106 treated cells injected into lethally irradiated CD45.1 
mice and homed SKL cells analysed 16 h post-transplant. Homing of human CD34+ cells 
was evaluated in NSG mice. UCB mononuclear cells were pulsed with dmPGE2 or vehicle 
and 4 × 107 cells transplanted into each of five sublethally irradiated (250 cGy) NSG mice. 
Homed CD34+ cells were analysed 16 h post-transplantation.
Analysis of CXCR4 expression and apoptosis
Mouse SKL cells or CD34+ UCB cells were pulsed with dmPGE2 or vehicle, washed and 
cultured in RPMI-1640 ⁄ 10% HI-FBS at 37 °C for 24 h. CXCR4 expression was analysed 
using CXCR4-PE. Apoptotic levels were measured with FITC-annexin-V or FITC-anti-
active caspase-3 after culture in RPMI-1640 ⁄ 2% HI-FBS at 37 °C for 24 h. For survivin and 
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active caspase-3 detection, cells were permeabilized and fixed using the CytoFix ⁄ CytoPerm 
kit (BD Biosciences) and stained with anti-active caspase-3-FITC Flow Kit (BD 
Biosciences) or survivin-PE (R&D Systems, Minneapolis, MN, USA).
Survivin and active caspase-3
Mouse SKL cells or CD34+ UCB cells were pulsed with dmPGE2 or vehicle, washed and 
cultured in RPMI-1640 ⁄ 10% HI-FBS at 37 °C for 24 h. CXCR4, survivin and ⁄ or active 
caspase-3 were analysed by FACS.
Migration assays
Chemotaxis to SDF-1a in vitro was determined as described previously (27). Briefly, 
dmPGE2-and vehicle-treated Lineageneg bone marrow cells, UCB CD34+ cells or peripheral 
blood CD34+ cells mobilized by G-CSF were cultured in RPMI ⁄ 10% HI-FBS overnight, 
washed, 2 × 105 cells added to the top chamber of transwells, with or without rmSDF-1α 
(R&D Systems) in the bottom chamber, and incubated for 4 h at 37 °C. Cells migrating to 
the bottom chamber were enumerated by FACS. Per cent migration was calculated by 
dividing total cells migrated to lower well, by cell input, multiplied by 100.
Cell cycle analysis
Lineageneg cells were treated with dmPGE2 or vehicle and cultured with rmSCF (50 ng ⁄ ml) 
(R&D Systems), rhFlt-3 and rhTPO (100 ng ⁄ ml each) (Immunex, Seattle, WA, USA) for 20 
h. Cells were stained for SLAM SKL, fixed, permeabilized and stained with Hoechst-33342 
followed by Pyronin-Y. Proportion of SLAM SKL cells in G0, G1, S and G2 ⁄ M phase was 
determined by FACS.
Statistical analysis
All pooled values are expressed as mean ± SEM. Statistical differences were determined 
using paired or unpaired two-tailed t-test functions with Microsoft Excel as appropriate.
Results
PGE2 increased long-term stem cell engraftment
Competitive repopulation transplantation models in mice allow for quantification of the 
ability of HSC to repopulate haematopoiesis. When congenic CD45.1 and CD45.2 mouse 
marrow cells were pulsed with vehicle or PGE2 and transplanted in a limiting-dilution 
fashion, into CD45.1 ⁄ CD45.2 hybrid mice, a model that permits head-to-head comparison 
of HSC populations; significantly enhanced HSC engraftment was observed for PGE2 -
pulsed bone marrow, compared to controls (Table 1). At 5 months post-transplantation, 
analysis of peripheral blood chimaerism showed significantly higher levels of white blood 
cells derived from PGE2-treated marrow cells. Analysis of HSC frequency by Poisson 
statistics or by calculation of competitive repopulating units (CRU), indicated an ~4-fold 
increase in HSC frequency, strongly suggesting a direct effect on HSC. These results agree 
with similar studies performed in a conventional congenic transplant model (26). Myeloid 
cells, B and T lymphocytes were reconstituted with no obvious bias in lineage 
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reconstitution. To validate self-renewal capacity of ex vivo PGE2-treated repopulating cells, 
marrow from primary transplantation recipients was harvested and transplanted into 
secondary recipients without any further ex vivo manipulation. Analysis of chimaerism at 24 
weeks after secondary transplantation also showed significantly increased contribution to 
chimaerism from PGE2-treated cells from primary recipients (Table 1). That enhanced 
chimaerism resulting from PGE2 exposure in primary donors was maintained in secondary 
transplants without additional treatment, indicated that the effect of PGE2 pulse exposure 
was stable and manifest in long-term repopulating stem cells (LT-HSC). On further serial 
trans-plantation, persistent enhanced chimaerism resulting from PGE2 pulse exposure prior 
to transplantation into primary donors, was observed. Transplantation of human 
haematopoietic cells in immunodeficient mice offers a model system to evaluate human 
HSC function in vivo (28). In a similar fashion to that shown using mouse bone marrow 
cells, short-term ex vivo pulse exposure to PGE2 enhanced engraftment of human UCB HSC 
in NOD ⁄ SCID-IL2-γ-receptor null (NSG) mice (Table 1).
PGE2 increased HSC homing efficiency
Effects on cell division, homing or proliferation can positively or negatively affect HSC 
function. As we have previously shown that PGE2 can have dual effects on haematopoiesis, 
we sought to define its mechanism of action to better understand the potential clinical utility 
of transient ex vivo PGE2 exposure. Successful haematopoietic reconstitution requires that 
administered haematopoietic cells traffic ⁄ home to bone marrow niches where they can 
engraft, self-renew and differentiate. We therefore evaluated effects of PGE2 exposure on 
these HSC functions.
To evaluate homing efficiency of HSC and determine whether the effect of PGE2 pulse 
exposure results from direct PGE2 effect, or is mediated through accessory cells, we FACS 
sorted congenic mouse Lineageneg Sca-1+, c-kit+ (SKL) cells, enriched for LT-HSC, treated 
them ex vivo and directly compared homing efficiency of PGE2-treated and vehicle-treated 
SKL cells head-to-head in CD45 hybrid mice. Pulse exposure of purified SKL cells to PGE2 
increased their homing efficiency 2-fold compared to controls (Fig. 2a). In traditional 
homing assays, increased homing of more differentiated Lineageneg, c-kit+ HPC and 
Lineageneg cells was not observed, suggesting that the enhanced homing effect of PGE2 is 
specific to HSC.
The CXCR4 and SDF-1a axis is a critical component of HSC marrow homing (29), and 
overexpression of CXCR4 in HSC enhances their in vivo homing and engraftment (30–32). 
To determine whether up-regulated CXCR4 would mediate PGE2-enhanced HSC marrow 
homing, marrow cells were treated ex vivo with selective CXCR4 antagonist AMD3100 (33) 
after PGE2 pulse exposure and prior to transplantation (Fig. 2b). As expected, PGE2 pulse 
exposure increased SKL cell homing. Incubation of vehicle or PGE2-pulsed cells with 
AMD3100 reduced SKL cell homing and abrogated PGE2 -improved homing efficiency. 
Reduction in HSC homing by AMD3100 is consistent with previous reports (34,35). To 
verify the enhancing effect of PGE2 on human cells, CD34+ cells were isolated from cord 
blood, pulsed with PGE2 or vehicle and their homing capacity analysed in NSG mice, a 
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validated model for human HSC homing (36). PGE2 pulse exposure significantly enhanced 
homing efficiency of human UCB CD34+ cells in NSG mice (Fig. 2c).
PGE2 increased HSC CXCR4 and migration to SDF-1α
As PGE2 enhancement of HSC homing was blocked by CXCR4 antagonism and PGE2 has 
been reported to upregulate CXCR4 on CD34+ cells (37) and endothelial cells (38), and 
increase monocyte chemotaxis to SDF-1α (39), we evaluated whether improved homing 
would result from HSC up-regulation of SDF-1α⁄ CXCR4 signalling and function. Pulse 
exposure to PGE2 increased CXCR4 expression on mouse SKL cells and human UCB 
CD34+ cells (Table 2). HSC selectively migrate to SDF-1α in vitro (40), a process that 
reflects their in vivo homing capacity. Vehicle-and PGE2-treated mouse SKL cells and 
CD34+ cells from human UCB and G-CSF mobilized peripheral blood all demonstrated 
significant migration to 100 ng ⁄ ml SDF-1α; however, in all cases, chemotaxis of PGE2-
treated cells was significantly higher (Table 2), indicating that up-regulation of HSC CXCR4 
coincided with enhanced migratory funct ion. The enhancing effect of PGE2 on chemotaxis 
to SDF-1α was blocked by AMD3100, indicating that the observed effect was mediated 
through the CXCR4 receptor.
PGE2 decreased apoptosis
Apoptosis is an important regulatory process in normal and malignant haematopoiesis and 
signalling downstream of PGE2 receptors has been implicated in anti-apoptotic effects (41–
43). This suggests that enhancement of HSC function by PGE2 could result from enhanced 
HSC survival. Under reduced serum conditions, pulse exposure to PGE2 reduced annexin-V 
and active caspase-3 in SKL cells, markers of apoptosis in mouse and human HSC (Fig. 
3a,b). Furthermore, intracellular levels of the endogenous caspase-3 inhibitor survivin, were 
significantly higher in both SKL and CD34+ cells, consistent with our previous findings that 
survivin regulated apoptosis and proliferation in HSC (44,45), and studies by others that 
PGE2 can increase survivin levels in cancer cells (46,47). QRT-PCR analysis of treated SKL 
cells and UCB CD34+ cells showed similarly elevated levels of survivin mRNA.
PGE2 increased entry of HSC into the cell cycle
We have previously shown that survivin regulates entry of HSC into the cell cycle and their 
progression through it (44,45). Furthermore, β-catenin, which is implicated in HSC 
proliferation ⁄ self-renewal, lies downstream of EP receptor pathways (48). Ability of PGE2 
to modulate these cell cycle regulators suggests that increase in HSC self-renewal and 
proliferation might contribute to enhanced engraftment observed using PGE2-pulsed cells. 
PGE2 pulse exposure significantly increased the proportion of primitive LT-HSC, defined as 
SLAM (CD150+, CD48–) SKL cells, in the cell cycle (G1 + S ⁄ G2M) compared to controls 
(Fig. 4). No significant effect on rate of cell cycle completion by HPC or more differentiated 
cells, was observed (data not shown), strongly suggesting that effects of PGE2 on cell cycle 
rate were selective.
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Discussion
In vivo analysis of effects of short-term pulse exposure to PGE2 clearly demonstrated that it 
has direct and stable effects on HSC function. Enhancement of HSC frequency and 
engraftment by PGE2 treatment results from effects on HSC homing and cell cycle activity 
involving up-regulation of CXCR4 and survivin, with increased chemotactic response to 
SDF-1α and reduced apoptosis. Ability to facilitate homing, survival and proliferation of 
HSC by short-term ex vivo PGE2 exposure offers an exciting clinical translation strategy to 
improve haematopoietic transplantation, specially in transplant settings characterized by low 
HSC numbers, such as with umbilical cord blood cells and some mobilized peripheral blood 
stem cell products. Our experimental pre-clinical limiting dilution transplantation studies 
show that equivalent engraftment is achieved with 4-fold fewer PGE2-treated cells compared 
to untreated cells. Homing and migration studies utilizing UCB CD34+ cells also clearly 
support potential translation of short-term PGE2 exposure to human haematopoietic grafts.
While ex vivo utility of PGE2 is clear, it will be interesting to determine whether enhanced 
HSC engraftment ⁄ recovery could also be achieved by administering PGE2 in vivo or if 
PGE2 used in vivo could further facilitate engraftment of HSC exposed to PGE2 ex vivo. In 
COX2 knockout mice, haematopoietic recovery from chemotherapy is delayed (49) 
suggesting that PGE2 production is critical for HSC expansion. However, it must be kept in 
mind that while short-term exposure to PGE2 can enhance HSC function, prolonged 
administration inhibits myelopoiesis (11,50), which is supported by inhibition of 
prostaglandin biosynthesis in vivo leading to expansion of myelopoiesis (51), at least in 
mice. Nevertheless, combination of transient ex vivo PGE2 exposure with selective 
modulation of in vivo PGE2 biosynthesis may result in significant further improvements in 
HSC function.
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Figure 1. Outline of prostaglandin E2 (PGE2) biosynthesis from membrane phospholipids.
COX, cyclooxygenase; PLA2, phospholipase A2.
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Figure 2. PGE2 pulse exposure enhances homing of mouse and human HSC.
(a) SKL cells were isolated from congenic mice by FACS sorting and treated with vehicle or 
1 µM 16, 16-dimethyl PGE2 (dmPGE2) on ice for 2 h. After incubation, cells were washed 
and 3 × 104 vehicle-or dmPGE2-treated CD45.1 and 3 × 104 vehicle-or dmPGE2-treated 
CD45.2 cells injected into lethally irradiated CD45.1 ⁄ CD45.2 hybrid mice. Number of 
homed CD45.1 and CD45.2 SKL cells was quantified in bone marrow at 16 h post-
transplantation. Data (mean ± SEM) from 10 mice with treatment groups of five mice, 
switched to rule out bias. (b) Bone marrow cells from CD45.2 mice were treated with 
vehicle or dmPGE2, washed, incubated in the presence or absence of 10 µM AMD3100 for 
30 min and transplanted into lethally irradiated CD45.1 mice. Number of homed CD45.2 
SKL cells was quantified in bone marrow at 16 h post-transplantation. Data (mean ± SEM) 
from three mice per group each assayed individually. (c) Umbilical cord blood mononuclear 
cells were isolated, treated with vehicle or dmPGE2 and injected into sublethally irradiated 
NSG mice. Bone marrow was analysed after 16 h for number of homed human CD45+, 
CD34+ cells. Data (mean ± SEM) from five mice per group each assayed individually.
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Figure 3. PGE2 decreases apoptosis and increases level of intracellular survivin.
(a) Lineage-depleted mouse bone marrow cells were treated with dmPGE2 or vehicle for 2 h, 
washed and cultured in 2% HI-FBS without growth factors for 24 h at 37 °C. After culture, 
cells were stained for SKL. Apoptosis was measured with FITC-annexin-V (left panel). 
Replicate cells were permeabilized and stained with anti-active caspase-3-FITC (middle 
panel) or anti-survivin-PE (right panel). Data expressed as fold-change induced by dmPGE2 
pulse exposure compared to vehicle-treated cells. (b) Fold-change in active caspase-3 (left 
panel) and intracellular survivin (right panel) in permeabilized PGE2-treated UCB CD34+ 
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cells relative to vehicle-treated cells after culture in 2% HI-FBS without growth factors for 
24 h at 37 °C.
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Figure 4. PGE2 increases cell cycle of SLAM SKL cells.
Lineage-depleted mouse bone marrow cells were treated with dmPGE2 or vehicle for 2 h, 
washed and cultured with 50 ng ⁄ ml rmSCF and 100 ng ⁄ ml each of rhFlt3 and rhTpo for 20 
h. Cells were stained for SLAM (CD150+, CD48–) ) SKL, Hoechst-33342 and pyronin-Y 
and proportion of SLAM SKL cells in G0, G1, S and G2 ⁄ M phases of the cell cycle 
determined by flow cytometry. Data (mean ± SEM) from nine mice each assayed 
individually. *P < 0.05.
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Table 1.
Transient exposure of haematopoietic cells to PGE2 enhances HSC engraftment
% PB chimaerism congenic miced
Group
Time of 
exposure (h)a
Fold increase 
HSC frequencyb Fold increase CRUc Primary Secondary
% PB
chimaerism NSGe
Vehicle 2 – – 13.3 ± 1.4 5.1 ± 0.13 2.3
1 µM dmPGE2 2 4.12 3.4 40.7 ± 5.0* 34.2 ± 0.51* 11.0
aWhole mouse bone marrow cells or human umbilical cord blood mononuclear cells were treated on ice with 0.001% ethanol or 1 µM dmPGE2 for 
2 h and washed twice in ice-cold PBS before transplant.
b
HSC cell frequency was calculated by Poisson statistics at 20 weeks post-transplant (P0 vehicle = 89 586; P0 PGE2 = 21 753) using L-CALC 
software (Stem Cell Technologies, Vancouver, BC, Canada).
cCRU were calculated based on PB chimaerism at 20 weeks in primary transplants according to the method of Harrison (24).
dChimaerism in PB is shown at 20 weeks in primary transplant and 24 weeks in secondary transplant (mean ± SEM). Data are for 10 mice in two 
experiments, each assayed individually.
eChimaerism in PB of NSG (NOD.Cg-Prkdcscid IL2rgtm1 Wjl ⁄ Sz) mice at 8 weeks post-transplant with vehicle-or PGE2-pulsed umbilical cord 
blood mononuclear cells.
*P < 0.05.
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Table 2.
PGE2 enhances mouse and human HSC CXCR4 expression and migration to SDF-1α
SKL cells UCB CD34+ cellsa MPB CD34+ cellsa
Vehicle dmPGE2
b Vehicle dmPGE2
b Vehicle dmPGE2
b
% increase CXCR4c 6.99 ± 2.5 26.82 ± 4.4* 6.88 17.31 – –
% migration to SDF-1d 46.8 ± 4.8 67.1 ± 5.7* 27.7 ± 1.2 55.6 ± 3.3* 23.2 ± 1.1 41.4 ± 1.8*
aCD34+ cells were isolated from umbilical cord blood or apheresis products of normal donors mobilized with G-CSF for allogeneic 
transplantation.
b
Mouse SKL cells or human CD34+ cells were treated on ice with 0.001% ethanol or 1 µM dmPGE2 for 2 h, washed, and resuspended in media 
with 10% HI-FCS and cultured at 37 °C for 16 h.
cCells were pulsed with dmPGE2 and cultured as described above. CXCR4 expression was analysed by flow cytometry. Data are expressed as 
percent-age change in mean fluorescence intensity of CXCR4 expression resulting from treatment with vehicle or dmPGE2.
dCells were pulsed with dmPGE2 and cultured as described above. After incubation, cells were washed, resuspended in RPMI ⁄ 0.5% BSA and 
allowed to migrate to 100 ng ⁄ ml recombinant mouse or human SDF-1a for 4 h. Total cell migration was quantified by flow cytometry. Data (mean 
± SEM) are from three experiments.
*P < 0.05.
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